2000-01-27T00:00:00
The National Institute for Clinical Excellences decision to reject the new flu treatment Relenza is a move the drug companies are not taking lying down.
With a HSJ subscription you’ll unlock:
Already a subscriber? Sign into your account here
Part of HSJ Information Ltd. 5th Floor, Aldgate Tower, 2 Leman Street, London E1 8FA. Registered in England and Wales. Company registration 2530185
Site powered by Webvision Cloud